Physician profile
Colette Nelson
NPI 1952525396
$21,158.01
in general payments reported to CMS, 2019-2025
11 companies · $8,427 in 2025
The $8,427 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $13K · 2025: $8,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $2,081 · Travel and Lodging: $427 · Consulting Fee: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,252.97 |
| Food and Beverage | $2,080.76 |
| Travel and Lodging | $427.28 |
| Consulting Fee | $397.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $17,462.63 | 2024-2025 | Omnipod, Omnipod |
| Tandem Diabetes Care, INC. | $1,314.29 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lumenis Be INC | $624.71 | 2024 | M22 |
| Roche Diabetes Care, INC. | $397.00 | 2024 | |
| Amgen INC. | $393.97 | 2025 | Repatha, Tepezza |
| Xeris Pharmaceuticals, INC. | $275.98 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $259.42 | 2025 | Korlym |
| Intra-Sana Laboratories | $203.82 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ascendis Pharma Endocrinology INC | $122.51 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $85.38 | 2025 | Twiist |
| Novo Nordisk INC | $18.30 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colette Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.